Robert W. Baird reiterated their hold rating on shares of Exactech (NASDAQ:EXAC) in a research report sent to investors on Thursday morning. The firm currently has a $49.00 price target on the medical equipment provider’s stock.

A number of other research analysts also recently issued reports on EXAC. BidaskClub upgraded shares of Exactech from a sell rating to a hold rating in a research report on Friday, August 18th. Sidoti downgraded shares of Exactech from a buy rating to a neutral rating in a research report on Monday, October 23rd. Gabelli downgraded shares of Exactech from a buy rating to a hold rating in a research report on Tuesday, October 24th. Zacks Investment Research downgraded shares of Exactech from a hold rating to a sell rating in a research report on Wednesday, October 25th. Finally, ValuEngine downgraded shares of Exactech from a buy rating to a hold rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Exactech has a consensus rating of Hold and an average price target of $49.00.

Exactech (EXAC) traded up $0.02 during trading on Thursday, reaching $50.30. 279,500 shares of the company’s stock were exchanged, compared to its average volume of 71,440. The company has a current ratio of 4.08, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. Exactech has a 52 week low of $23.30 and a 52 week high of $50.95. The firm has a market cap of $724.99, a P/E ratio of 41.57, a PEG ratio of 4.05 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.22%. The business had revenue of $61.40 million for the quarter, compared to analyst estimates of $61.78 million. research analysts expect that Exactech will post 1.29 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new stake in shares of Exactech in the 2nd quarter valued at approximately $134,000. Highbridge Capital Management LLC bought a new stake in Exactech during the 3rd quarter worth approximately $201,000. Hancock Holding Co. bought a new stake in Exactech during the 2nd quarter worth approximately $212,000. AMP Capital Investors Ltd bought a new stake in Exactech during the 3rd quarter worth approximately $215,000. Finally, Janney Montgomery Scott LLC bought a new stake in Exactech during the 2nd quarter worth approximately $233,000. Institutional investors and hedge funds own 66.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/11/exactech-exac-stock-rating-reaffirmed-by-robert-w-baird.html.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Receive News & Stock Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related stocks with our FREE daily email newsletter.